-
Celgene’s Abraxane fails pancreatic cancer trial
13 Mar 2019 14:04 GMT
… recurring.
The APACT trial compared Abraxane plus gemcitabine given after surgery … the study – was improved with Abraxane, reaching “nominal statistical significance”, according … frontline metastatic squamous non-small cell lung cancer.
It secured another this week …
-
Celgene Provides Update on ABRAXANE® Combination Therapy in the Treatment of Metastatic Triple-Negative Breast Cancer and Pancreatic Cancer
12 Mar 2019 22:08 GMT
… statistical significance, with ABRAXANE in combination with … non–small cell lung cancer, in combination with … Lung Cancer (NSCLC) Study
The most common adverse reactions (≥20%) of ABRAXANE … atrioventricular block with ABRAXANE, primarily among individuals …
-
FDA Accepts Genentech’s Supplemental Biologics License Application for Tecentriq Plus Chemotherapy (Abraxane and Carboplatin) for the Initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
17 Jan 2019 07:01 GMT
… (atezolizumab) in combination with Abraxane ® (albumin-bound paclitaxel; nab … chemotherapy alone.
About Lung Cancer
According to … lung cancers. It is estimated that approximately 60 percent of lung cancer …
About Genentech in Lung Cancer
Lung cancer is a major …
-
3 Cancer Treatment Stocks to Buy in March
23 Mar 2019 17:41 GMT
… potential drug for RET-altered lung cancer, medullary thyroid cancer, and … is testing PEGPH20 with Abraxane from Celgene and gemcitabine … treating patients with advanced lung cancer was often ethically … the death rate from lung cancer dropped in half. …
-
US FDA accepts Roche's sBLA for Tecentriq in combo with Abraxane and carboplatin to treat metastatic NSCLC
18 Jan 2019 04:26 GMT
… atezolizumab) in combination with Abraxane [albumin-bound paclitaxel; nab-paclitaxel]) … non-squamous non-small cell lung cancer (NSCLC) who do … non-squamous non-small cell lung cancer as soon as … non-squamous and squamous-cell lung cancer, the squamous form …
-
Genentech’s combination therapy improves outcome in patients with non-squamous non-small cell lung cancer
22 Oct 2018 11:19 GMT
… ® (atezolizumab) plus chemotherapy (carboplatin and Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) for the … untreated metastatic non-squamous non-small cell lung cancer (NSCLC). The analysis showed that … non-squamous non-small cell lung cancer, the most common form of lung cancer," said …
-
Roche Holding Ltd (RHHBY) Management on Virtual Pipeline Event 2018 World Conference on Lung Cancer Conference Call (Transcript)
26 Sep 2018 22:13 GMT
… Small-cell lung cancer accounts for about 15% of all lung cancers, … , ROS1-inhibitor-naïve, non-small cell lung cancer patients.
So let’ … in ROS1-positive non-small cell lung cancer and patients treated … survival, including the abraxane combination and the …
-
BeiGene Presents Results on Anti-PD-1 Antibody Tislelizumab in Chinese Patients with Lung Cancers at the Annual Meeting of the Chinese Society of Clinical Oncology
21 Sep 2018 03:38 GMT
… in Chinese patients with lung cancers, in two oral … advanced or metastatic lung cancer. All patients received … of Lung Cancer (IASLC) 19th World Conference on Lung Cancer (WCLC … patients. BeiGene markets ABRAXANE® (nanoparticle albumin–bound paclitaxel …
-
BeiGene to Present Data on Anti-PD-1 Antibody Tislelizumab at the IASLC 19th World Conference on Lung Cancer (WCLC) in Toronto
05 Sep 2018 21:05 GMT
… Advanced Lung Cancer
Session 1:
JCSE01 – Perspectives for Lung Cancer … with Non-Small Cell Lung Cancer (NSCLC)
Poster:
P2 … patients. BeiGene markets ABRAXANE® (nanoparticle albumin–bound … .com ________________________
1 ABRAXANE®, REVLIMID®, and VIDAZA® …
-
Celgene Presents An Attractive Short-Term Investment Opportunity In March 2019
20 Mar 2019 20:49 GMT
… demonstrate its efficacy in first-line lung cancer indication in the Phase 3 … lung cancer indication, as penetration of immunotherapy increases in the first line lung cancer … commercial assets such as Pomalyst, Abraxane, and Otezla to Bristol-Myers Squibb …
About
© 1995-2019